Anti-atherosclerotic effect of betaine in apolipoprotein E-deficient mice.
- Author:
Rui-xin FAN
1
;
Shi-wei LÜ
;
Yan-ping DU
;
Meng-jun HOU
;
Hui-lian ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Apolipoproteins E; deficiency; genetics; Atherosclerosis; blood; drug therapy; Betaine; pharmacology; therapeutic use; Chemokine CCL2; metabolism; Dietary Supplements; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Tumor Necrosis Factor-alpha; metabolism
- From: Chinese Journal of Preventive Medicine 2008;42(10):742-747
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of betaine on the formation of atherosclerotic plaque in apolipoprotein E (ApoE)-deficient mice and explore its anti-inflammatory mechanism.
METHODSSeven-week-old ApoE-deficient mice (C57BL/6J background) were divided into four groups randomly based on body weight: model group and three betaine groups. Wild-type mice with the same age and genetic background were used as control group. The control group and model group were fed AIN-93G diet. Three betaine groups were fed AIN-93G diet supplemented with 1, 2, 4 g betaine/100 g diet, respectively. Serum tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1, lipid levels and methylation status of TNF-alpha promotor in aorta were determined at 0, 7 and 14 weeks. The percentage of aorta sinus plaque to lumen area was measured at 14-week.
RESULTSThe percentage of aorta sinus plaque to lumen area of 1% and 2% betaine groups were (11.43+/-2.65)% and (12.09+/-3.07)%, respectively, which were 41% and 33% smaller than that of the model group (t=3.117, 3.010, respectively, and P<0.01). Serum TNF-alpha level of three betaine groups were (56.33+/-3.86), (63.04+/-4.67) and (65.52+/-3.97) pg/ml, respectively, which were lower than that of the model group (79.40+/-4.68) pg/ml (t=9.270, 6.571 and 5.576, respectively, P<0.001), but there was no significant difference in the methylation status of TNF-alpha promotor among all five groups.
CONCLUSIONBetaine could inhibit the development of atherosclerosis via anti-inflammation.